There was a tacit understanding that designers and engineers needed to sort out the buildings and services and that operations managers would work on what goes on inside the buildings.
After assisting in the development of a pre-fabricated node module for Heathrow Terminal 5, he took on a new role in the company developing innovative design solutions utilising BIM and.Design for Manufacture and Assembly (DfMA).
As part of this role Adam was involved in the design and construction of the EcoCanopy modular school system..Following this experience Adam became involved in the design of larger scale development projects incorporating BIM and DfMA techniques, initially working on the 2012 Athletes’ Village and East Village projects, followed by the design and implementation of a standardised “chassis” solution for a mixed-use residential development.Some of the concepts developed at this time have contributed to Bryden Wood’s Platform approach to DfMA..
Recently Adam became involved as a project leader in the development of early stage design concepts and business case alignment for the Front End Factory initiative with GlaxoSmithKline (GSK), utilising advanced digital tools and off-site manufactured components for GSK’s portfolio of global capital projects.This work was key to the development of Bryden Wood’s Chip Thinking™ approach.. Adam is also building contacts and exploring DfMA opportunities in Asia/Pacific.
Adam is recognised for his experience in.
and DfMA and regularly participates in talks, seminars and other industry events across the region.Maria is a Director in the Creative Technologies team and focuses on our work in algorithmic and.Drastic reduction in the cost of sequencing the human genome, setting a record for the fastest learning curve in history..
Global deployment of SARS-CoV-2 vaccines within a year.. Development of mRNA vaccines targeting previously untreatable diseases like cancer and autoimmune disorders, expected to be available by 2030..Significant increase in the approval and use of advanced therapy medicinal products (ATMPs) such as cell and gene therapies, which were introduced just 14 years ago.. 400 times increase in FDA clinical trials for new drugs in the past two decades..
Rapid expansion of bio-revolution into various sectors like agriculture, consumer goods, bio-services, bio-computing, bio-informatics, and bio-industry..These advancements, combined with broader societal, political, and economic trends, are projected to double the size of the life science market within the next decade..